Novel biologics for treatment of chronic spontaneous urticaria

被引：9

作者：

Casale, Thomas B. ^{[1
]}

机构：

[1] Univ S Florida, Dept Med, Div Allergy Immunol, Morsani Coll Med, 12901 Bruce B Downs St,MDC 19, Tampa, FL 33612 USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2022年 / 150卷 / 06期

关键词：

Urticaria; biologics; mast cells; OMALIZUMAB;

D O I：

10.1016/j.jaci.2022.06.027

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Chronic idiopathic/spontaneous urticaria (CIU/CSU) causes significant impairments in quality of life and is often unresponsive to antihistamines. Although the anti-IgE mAb omalizumab has been an important addition to the therapeutic armamentarium for the management of patients with CSU, there are still a significant percentage of patients who do not respond to the combination of antihistamines and omalizumab. As a result, additional treatments are needed. With the expanding knowledge of the pathogenesis of CSU and the role of mast cells, novel therapeutic agents targeting unique pathways important in CSU are in development. This review focuses on the rationale behind, and results of, novel therapies trialed in CSU.

引用

页码：1256 / 1259

页数：4

共 30 条

[1] An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria [J].

Altrichter, Sabine ;

Staubach, Petra ;

Pasha, Malika ;

Singh, Bhupinder ;

Chang, Alan T. ;

Bernstein, Jonathan A. ;

Rasmussen, Henrik S. ;

Siebenhaar, Frank ;

Maurer, Marcus .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (05) :1683-+

[2]

[Anonymous], 2022, PRESS REL

[3]

[Anonymous], 2021, GlobeNewsWire

[4] Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria [J].

Arnau A M, Gimenez ;

Santiago A, Valero ;

Tomas J, Bartra ;

Presa I, Jauregui ;

Labrador-Horrillo, M. ;

Miquel F J, Miquel ;

de Frutos J, Ortiz ;

Sastre, J. ;

Salvador J F, Silvestre ;

Puga M, Ferrer .

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2019, 29 (05) :338-348

[5] Treatment of chronic spontaneous urticaria with benralizumab: Report of primary endpoint per-protocol analysis and exploratory endpoints [J].

Bernstein, Jonathan A. ;

Singh, Umesh ;

Rao, Marepalli B. ;

Berendts, Karen ;

Zhang, Xiang ;

Mutasim, Diya .

ALLERGY, 2021, 76 (04) :1277-1280

[6] Benralizumab for Chronic Spontaneous Urticaria [J].

Bernstein, Jonathan A. ;

Singh, Umesh ;

Rao, Marepalli B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14) :1389-1391

[7] Chronic Urticaria in the Real-Life Clinical Practice Setting in Portugal: Baseline Results from the Non-Interventional Multicentre AWARE Study [J].

Costa, Celia ;

Rosmaninho, Isabel ;

Guilherme, Arminda ;

Ferreira, Jose ;

Antunes, Joana ;

Pina, Ana ;

Prates, Sara ;

Marques, Joao Gaspar ;

Azevedo, Filomena ;

Cunha, Ana Paula ;

Brito, Celeste ;

Massa, Antonio ;

de Sousa, Joao Teles ;

Velho, Gloria Cunha ;

Raposo, Ines ;

Pinto, Gabriela Marques ;

Sousa, Virginia ;

Martins, Ana Rodrigues .

ACTA MEDICA PORTUGUESA, 2019, 32 (02) :133-140

[8] Emerging Biomarkers and Therapeutic Pipelines for Chronic Spontaneous Urticaria [J].

Deza, Gustavo ;

Ricketti, Peter A. ;

Gimenez-Arnau, Ana M. ;

Casale, Thomas B. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2018, 6 (04) :1108-1117

[9] Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis [J].

Dispenza, Melanie C. ;

Krier-Burris, Rebecca A. ;

Chhiba, Krishan D. ;

Undem, Bradley J. ;

Robida, Piper A. ;

Bochner, Bruce S. .

JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (09) :4759-4770

[10] Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria [J].

Kaplan, Allen ;

Ferrer, Marta ;

Bernstein, Jonathan A. ;

Antonova, Evgeniya ;

Trzaskoma, Benjamin ;

Raimundo, Karina ;

Rosen, Karin ;

Omachi, Theodore A. ;

Khalil, Sam ;

Zazzali, James L. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) :474-481

← 1 2 3 →